Department of Stomatology, First Hospital of Longhai City, Longhai, Fujian, China; School and Hospital of Stomatology, Fujian Medical University, Fuzhou, Fujian, China.
Research Centre of Dental and Craniofacial Implants, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, Fujian, China.
Int J Oral Maxillofac Surg. 2022 Aug;51(8):1078-1084. doi: 10.1016/j.ijom.2021.10.010. Epub 2022 Jan 7.
The aim of this study was to compare the clinical effects of osteotome sinus floor elevation (OSFE) combined with concentrated growth factor (CGF) and simultaneous implant placement with or without bone grafting in the maxillary posterior region, where the residual bone height (RBH) was 4-6 mm. A total of 44 patients who underwent OSFE combined with CGF and the simultaneous placement of 60 implants (group A, 31 implants with bone grafting; group B, 29 implants without bone grafting) were included in this retrospective study. The clinical indicators of implants were observed for 24 months. Sinus floor lift height was 6.02 ± 0.99 mm in group A and 5.81 ± 0.72 mm in group B (P = 0.360) after surgery. There was no significant difference in the vertical bone resorption between the two groups at 24 months (P = 0.097). Postoperative pain at 14 days (visual analogue scale) was significantly greater in patients with bone grafting when compared to those without bone grafting (P < 0.001). There was no significant difference in marginal bone loss (MBL) between the two groups (P = 0.707 for MBL during the first 12 months, P = 0.922 for MBL during months 12-24). The implant success rate was 100% with or without bone grafting. The technique of OSFE with CGF, either with or without bone grafting, is safe and reliable in patients with RBH 4-6 mm.
本研究旨在比较经皮上颌窦底提升术(OSFE)联合浓缩生长因子(CGF)和同期种植在剩余骨高度(RBH)为 4-6mm 的上颌后牙区的临床效果,其中 60 个种植体(A 组 31 个种植体伴骨移植;B 组 29 个种植体不伴骨移植)。观察 24 个月的种植体临床指标。术后 A 组窦底提升高度为 6.02±0.99mm,B 组为 5.81±0.72mm(P=0.360)。两组 24 个月时垂直骨吸收无显著差异(P=0.097)。术后 14 天(视觉模拟评分)伴骨移植患者的疼痛明显大于不伴骨移植患者(P<0.001)。两组间边缘骨吸收无显著差异(第 12 个月的 MBL 为 P=0.707,第 12-24 个月的 MBL 为 P=0.922)。无论是否伴骨移植,种植体成功率均为 100%。对于 RBH 为 4-6mm 的患者,OSFE 联合 CGF 技术,无论是否伴骨移植,均安全可靠。